| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/TRF.12198 |
| P698 | PubMed publication ID | 23607889 |
| P2093 | author name string | Shan Yuan | |
| Amrita Krishnan | |||
| Sepideh Shayani | |||
| Auayporn Nademanee | |||
| Neil Kogut | |||
| Shirong Wang | |||
| P2860 | cites work | How I treat patients who mobilize hematopoietic stem cells poorly | Q28245316 |
| Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy | Q33861711 | ||
| Defining a Therapeutic Dose of Peripheral Blood Stem Cells | Q35174810 | ||
| Improving stem cell mobilization strategies: future directions | Q37367235 | ||
| Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens | Q37533983 | ||
| Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept | Q37943423 | ||
| Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization | Q42623080 | ||
| Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio | Q43282877 | ||
| The EBMT activity survey 2008: impact of team size, team density and new trends | Q43754303 | ||
| Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization | Q44433507 | ||
| Use of plerixafor in patients with Hodgkin lymphoma with poor mobilization of peripheral blood stem cells | Q44513387 | ||
| Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. | Q44556507 | ||
| A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma | Q46305389 | ||
| Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. | Q51371230 | ||
| Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. | Q51431592 | ||
| Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. | Q51705517 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3244-3250 | |
| P577 | publication date | 2013-04-22 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent | |
| P478 | volume | 53 |
| Q46089696 | Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization |
| Q38978669 | How do we mobilize and collect autologous peripheral blood stem cells? |
| Q39677517 | Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation |
| Q91452397 | The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma |
| Q48251584 | UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. |
Search more.